Immunome, Inc. (NASDAQ:IMNM) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Analysts' consensus: Eleven firms give Immunome a "Moderate Buy" consensus (10 buys, 1 sell) with an average 12‑month target of $33.45, versus the current price near $22.90, implying notable upside.
• Operational and insider signals: Immunome missed Q1 EPS estimates (reported -$0.75 vs. -$0.65 expected), and insiders have recently sold material stakes (139,438 shares worth ~$2.96M over 90 days), while institutions own ~44.6% and insiders ~7.7%.

Shares of Immunome, Inc. (NASDAQ:IMNM - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the eleven research firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and ten have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $33.4545.

A number of research analysts have weighed in on IMNM shares. Lake Street Capital raised their target price on shares of Immunome from $22.00 to $32.00 and gave the stock a "buy" rating in a research note on Tuesday, December 16th. Wedbush reissued an "outperform" rating and issued a $31.00 target price on shares of Immunome in a research note on Thursday, January 15th. Wall Street Zen lowered shares of Immunome from a "hold" rating to a "sell" rating in a research note on Saturday, March 7th. Weiss Ratings reissued a "sell (d-)" rating on shares of Immunome in a research note on Thursday, January 22nd. Finally, Stephens decreased their target price on shares of Immunome from $33.00 to $30.00 and set an "overweight" rating on the stock in a research note on Wednesday, March 4th.

Immunome Trading Up 1.2%

Shares of Immunome stock opened at $22.90 on Wednesday. The firm has a market capitalization of $2.59 billion, a PE ratio of -9.46 and a beta of 2.13. Immunome has a twelve month low of $6.96 and a twelve month high of $27.65. The firm's 50-day moving average price is $21.86 and its 200 day moving average price is $19.94.

Immunome (NASDAQ:IMNM - Get Free Report) last released its earnings results on Tuesday, March 3rd. The company reported ($0.75) earnings per share for the quarter, missing analysts' consensus estimates of ($0.65) by ($0.10). On average, sell-side analysts predict that Immunome will post -2.21 EPS for the current fiscal year.

Insiders Place Their Bets

In other Immunome news, Director Philip Wagenheim sold 36,800 shares of the firm's stock in a transaction that occurred on Friday, March 20th. The shares were sold at an average price of $20.47, for a total value of $753,296.00. Following the transaction, the director directly owned 369,347 shares of the company's stock, valued at $7,560,533.09. This trade represents a 9.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Jack Higgins sold 9,438 shares of the firm's stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $21.64, for a total transaction of $204,238.32. Following the sale, the insider owned 22,000 shares of the company's stock, valued at $476,080. This represents a 30.02% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 139,438 shares of company stock valued at $2,964,664 in the last ninety days. 7.69% of the stock is currently owned by corporate insiders.

Institutional Trading of Immunome

A number of hedge funds and other institutional investors have recently made changes to their positions in IMNM. Assetmark Inc. acquired a new stake in shares of Immunome during the 3rd quarter worth approximately $39,000. BNP Paribas Financial Markets increased its holdings in shares of Immunome by 81.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company's stock worth $60,000 after buying an additional 2,909 shares during the last quarter. Strs Ohio acquired a new stake in shares of Immunome during the 4th quarter worth approximately $64,000. Tower Research Capital LLC TRC increased its holdings in shares of Immunome by 121.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company's stock worth $65,000 after buying an additional 3,802 shares during the last quarter. Finally, BIT Capital GmbH acquired a new stake in shares of Immunome during the 3rd quarter worth approximately $69,000. Institutional investors and hedge funds own 44.58% of the company's stock.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome's approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company's lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.